Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for pain and related disorders
The company is dedicated to addressing unmet medical needs through its advanced therapeutic candidates, which aim to provide safe and effective alternatives to existing pain management options. By leveraging its expertise in neuroscience and pharmacology, Relmada Therapeutics is working towards advancing novel therapies that enhance the quality of life for patients suffering from chronic pain conditions and other neurological issues.
Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals.
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSETME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million.
The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Shares of Mobileye Global Inc. (NASDAQMBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<
Relmada Therapeutics Inc (NASDAQRLMD) announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3 trial (Study 310) of REL-1017 in patients with
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSETAK) is likely to report earnings for its fourth quarter. • Exela Technologies NASDAQ:XELANASDAQXELA)
